Superworth

Yarrow Bioscience revenue YARW

Sales by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
$97K
+41% on a year earlier
Fiscal year 2024
$501K
+18% on the year before

Yarrow Bioscience's twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was $97K, up 41% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$501K+18%
FY2023$424K−11%
FY2022$477K−49%
FY2021$931K−96%
FY2020$21M+4639%
FY2019$443K−96%
FY2018$10.6M+132%
FY2017$4.6Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$97K+41%n/a
Q1 FY26$86K−57%n/a
Q2 FY25$69K−65%$476K
Q1 FY25$202K+106%$605K
Q4 FY24$84K+11%$501K
Q3 FY24$121K+6%$493K
Q2 FY24$198K+47%$486K
Q1 FY24$98K−1%$423K
Q4 FY23$76K+1167%$424K
Q3 FY23$114K−32%$354K
Q2 FY23$135K+7%$407K
Q1 FY23$99K−44%$398K

Against its peers

Companies in Drug Manufacturers - General nearest Yarrow Bioscience's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
YARWYarrow Biosciencen/m
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
Peer median$249.6M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Yarrow Bioscience

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.